Type I interferon (IFN) score may effectively predict disease progression in limited cutaneous systemic sclerosis (lcSSc), with patients having a high IFN activity presenting worse clinical outcomes.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback